- Products
- Flow Cytometry
- Biotheraputics Discovery
- Custom Services
- Bioanalytical Antibodies
- Tools and Resources
- Antibody Support
- Order Status
- Quick Order
- Support
Browsing Modes for Business Users
-
Create mode – the default mode when you create a requisition and PunchOut to Bio-Rad. You can create and edit multiple shopping carts
-
Edit mode – allows you to edit or modify an existing requisition (prior to submitting). You will be able to modify only the cart that you have PunchedOut to, and will not have access to any other carts
-
Inspect mode – when you PunchOut to Bio-Rad from a previously created requisition but without initiating an Edit session, you will be in this mode. You cannot modify any Cart contents
Anti-Secukinumab Antibodies
-
Bioanalytical Antibodies
-
Antibodies for Bioanalysis and Drug Monitoring
-
Our Anti-Biotherapeutic Antibodies
- Anti-Abatacept Antibodies
- Anti-Adalimumab Antibodies
- Anti-Aflibercept Antibodies
- Anti-Alemtuzumab Antibodies
- Anti-Atezolizumab Antibodies
- Anti-Avelumab Antibodies
- Anti-Belatacept Antibodies
- Anti-Bevacizumab Antibodies
- Anti-Brentuximab Antibodies
- Anti-Cemiplimab Antibodies
- Anti-Certolizumab Antibodies
- Anti-Cetuximab Antibodies
- Anti-Daratumumab Antibodies
- Anti-Denosumab Antibodies
- Anti-Dupilumab Antibodies
- Anti-Durvalumab Antibodies
- Anti-Eculizumab Antibodies
- Anti-Etanercept Antibodies
- Anti-Evolocumab Antibodies
- Anti-Golimumab Antibodies
- Anti-Infliximab Antibodies
- Anti-Ipilimumab Antibodies
- Anti-Natalizumab Antibodies
- Anti-Nivolumab Antibodies
- Anti-Obinutuzumab Antibodies
- Anti-Ocrelizumab Antibodies
- Anti-Omalizumab Antibodies
- Anti-Palivizumab Antibodies
- Anti-Panitumumab Antibodies
- Anti-Pembrolizumab Antibodies
- Anti-Pertuzumab Antibodies
- Anti-Ranibizumab Antibodies
- Anti-Rituximab Antibodies
- Anti-Sarilumab Antibodies
- Anti-Secukinumab Antibodies
- Anti-Tocilizumab Antibodies
- Anti-Trastuzumab Antibodies
- Anti-Ustekinumab Antibodies
- Anti-Vedolizumab Antibodies
-
Our Anti-Biotherapeutic Antibodies
-
Antibodies for Bioanalysis and Drug Monitoring
s
s
s
Antibodies for bioanalysis and drug monitoring of secukinumab and biosimilars
Develop highly selective and sensitive PK and ADA assays for the monoclonal antibody secukinumab (Cosentyx) using our range of ready-made antibodies.
- Highly specific to secukinumab or the secukinumab-IL17A complex
- Fully human format for surrogate positive control or calibrator
- Sequence-defined, well characterized reagents with secure supply
- Stringent quality control for batch-to-batch consistency
- Nonanimal-derived antibodies, reducing the use of animals in science
Table 1. Antibodies Specific to Secukinumab.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
|---|---|---|---|---|---|---|
|
Secukinumab Inhibitory Type 1 |
HCA370 |
AbD37052 |
Fab-FH1 |
5 |
PK bridging ELISA |
|
|
HCA371 |
AbD37054ia |
Human IgG1 |
3 |
PK bridging ELISA ADA control |
||
|
HCA372 |
AbD37091ia |
Human IgG1 |
5 |
PK bridging ELISA ADA control |
||
|
HCA373 |
AbD36536ia |
Human IgG1 |
12 |
ADA control |
||
|
Secukinumab-IL17A Complex Specific Type 3
|
HCA375 |
AbD36949 |
Fab-FH1 |
7 |
PK antigen capture ELISA |
* Affinity measured in the monovalent Fab format.
1 Monovalent Fab antibody (F) DYKDDDDK- and (H) His-6-tags
Anti-Secukinumab Inhibitory Antibodies (Type 1)
Type 1 anti-secukinumab antibodies inhibit the binding of the monoclonal antibody drug secukinumab to its target, human interleukin 17A (IL-17A). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. They are available in fully human IgG1 format, in three different affinities, for use as a surrogate positive control or reference standard for an anti-drug antibody (ADA) assay.
Anti-Secukinumab-IL17A Complex Specific Antibody (Type 3)
The Type 3 antibody specifically recognizes the drug-target complex, detecting secukinumab only when it is bound to IL17A. It is suitable as a detection antibody in a PK antigen capture assay, as an alternative assay format to the bridging ELISA.
ELISA Protocols to Get You Started
PK Bridging ELISA
Fig. 1. Secukinumab PK bridging ELISA using antibodies HCA370 and HCA372.
Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.
PK Antigen Capture ELISA
Fig. 2. Secukinumab PK antigen capture ELISA using antibody HCA375.
Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug-target complex detection antibody, monovalent Fab format (purple), anti-tag detection antibody labeled with HRP (gray).
ADA Bridging ELISA
Fig. 3. Secukinumab ADA bridging ELISA using antibody HCA371, HCA372, or HCA373.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Related Products
Resources
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.